Global Kidney Cancer Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Test (Immunohistochemistry, Complete Blood Count, Urine Test, and Blood Chemistry), By Indication (Renal Cell Carcinoma, Transitional Cell Carcinoma, Kidney Sarcoma, Wilms Tumor, and Kidney Lymphoma), By End-User (Hospital-Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, and Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Kidney Cancer Diagnostics Market Insights Size Forecasts to 2035

• The Global Kidney Cancer Diagnostics Market Size Was Estimated at USD 5.37 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.11% from 2025 to 2035
• The Worldwide Kidney Cancer Diagnostics Market Size is Expected to Reach USD 8.36 Billion by 2035
• Asia Pacific is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights & Consulting, The Global Kidney Cancer Diagnostics Market Size was valued at approximately USD 5.37 Billion in 2024 and is projected to Grow from USD 5.59 Billion in 2025 to around USD 8.36 billion by 2035, at a compound annual growth rate (CAGR) of 4.11% during the forecast period (2025–2035). There is increasing consumer awareness of early detection and personalized medicine, with an increasing global prevalence of cancer. The kidney cancer diagnostics market is showing strong growth with an increasing prevalence of kidney cancer and upsurging advancements in diagnostic technologies such as imaging, liquid biopsy, and AI.

Global Kidney Cancer Diagnostics Market Forecast and Revenue Outlook

• 2024 Market Size: USD 5.37 Billion
• 2035 Projected Market Size: USD 8.36 Billion
• CAGR (2025-2035): 4.11%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Market Overview

The kidney cancer diagnostics market is the cancer diagnostics industry, emphasizing the development and sale of medical tools, technologies, and services that are used for early detection, diagnosis, staging, and monitoring of kidney cancer. Kidney cancer diagnostics involve the medical history and physical examination. The diagnostic tests further include urine analysis, blood tests, CT scan, MRI scan, ultrasound, chest x-ray, angiography, bone scan, and kidney biopsy. More than 431,000 new cases of kidney cancer were estimated globally in 2022, according to the WHO. The aging population and other lifestyle-related factors like smoking, obesity, hypertension, and environmental exposures are responsible for the increased prevalence rate of kidney cancer. The awareness among patients about kidney health leads to driving the demand for early diagnosis in order to detect the diseases at the initial stage. Furthermore, technological advancements and innovations in diagnostic solutions are improving the ability of diagnostic tools to detect and differentiate kidney tumors.

The global market share is anticipated to be supported by expanding R&D efforts by major industry participants and funding for developing a therapy for kidney cancer. There are opportunities in the developing market due to the growing healthcare infrastructure and the integration of technological advancements and innovative solutions in the devices. For instance, in June 2025, the American Kidney Fund (AKF) launched a kidney cancer education campaign.

Key Market Insights

• North America is expected to account for the largest share in the Kidney Cancer Diagnostics Market during the forecast period.
• In terms of test, the immunohistochemistry segment is projected to lead the kidney cancer diagnostics Market throughout the forecast period
• In terms of indication, the renal cell carcinoma segment captured the largest portion of the market
• In terms of end-user, the hospital-associated labs segment leads the market with the largest share.

Kidney Cancer Diagnostics Market Trends

• Adoption of liquid biopsies for non-invasive detection
• Integration of artificial intelligence and machine learning
• Advanced imaging and incidental findings on CT/MRI scans
• Genetic testing for identifying high risk hereditary kidney cancer

Report Coverage

This research report categorizes the kidney cancer diagnostics market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the kidney cancer diagnostics market. Recent market developments and competitive strategies, including expansion, type launches, development, partnerships, mergers, and acquisitions, have been incorporated to illustrate the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the kidney cancer diagnostics market.

Driving factors

The kidney cancer diagnostics market is primarily driven by the increasing prevalence of kidney cancer, awareness about early diagnostics, and technological advancements in diagnostic devices. It was estimated that there are 400,000 new cases of kidney cancer annually, with a mortality rate approaching 175,000 deaths per year. Thus, increasing concern over cancer incidence and mortality drives the need for diagnostic tools. Further, technological advancements in diagnostics, including the integration of radiomics and AI into routine clinical practice, aid in propelling market growth.

Restraining Factor

One of the main factors restraining the kidney cancer diagnostics market is the lack of awareness regarding early diagnostics and kidney screening programs in the emerging and underdeveloped regions. Further, the increased cost of advanced diagnostic tools is hampering adoption, especially in the low and middle-income countries, which is challenging the market growth.

Market Segmentation 

The global kidney cancer diagnostics market is divided into test, indication, and end-user.

Global Kidney Cancer Diagnostics Market, By Test:

• The immunohistochemistry segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period.   

Based on test, the global kidney cancer diagnostics market is segmented into immunohistochemistry, complete blood count, urine test, and blood chemistry. Among these, the immunohistochemistry segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Immunohistochemistry aids in identifying specific protein markers on cancer cells within a sample, revealing the exact type and subtype of cancer by visualizing the distribution and localization of specific cellular components within tissue samples.

The urine test segment is anticipated to grow at the fastest CAGR during the forecast period, due to its accessibility and non-invasiveness. Urine analysis for kidney cancer helps in detecting cancer cells through urine cytology and further definitive tests.

Global Kidney Cancer Diagnostics Market, By Indication:

• The renal cell carcinoma segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on indication, the global kidney cancer diagnostics market is segmented into renal cell carcinoma, transitional cell carcinoma, kidney sarcoma, Wilms tumor, and kidney lymphoma. Among these, the renal cell carcinoma segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Renal cell carcinoma is a common type of kidney cancer, accounting for 85-90% of all kidney malignancies. Diagnostics techniques like CT/MRI imaging, immunohistochemistry, and molecular biomarker testing are used for detection and characterization. Renal cell carcinoma causing factors like advanced age, smoking, obesity, hypertension, and certain medications contribute to driving the market demand in the renal cell carcinoma segment.

The Wilms tumor segment is anticipated to grow at the fastest CAGR during the projected period. This is attributed to the increasing prevalence of Wilms tumor and surging government initiatives & investments in pediatric cancers. Wilms’ tumor is nephroblastoma, the most common kidney cancer affecting those under the age of five.

Global Kidney Cancer Diagnostics Market, By End-User:

• The hospital-associated labs segment is anticipated to account for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on end-user, the global kidney cancer diagnostics market is segmented into hospital-associated labs, independent diagnostic laboratories, cancer research institutes, and others. Among these, the hospital-associated labs segment is anticipated to account for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. An in-hospital laboratory is a facility within a hospital equipped to perform a wide range of diagnostic tests and analyses on patient samples. Further, the availability of multidisciplinary oncology teams for prompt testing and treatment decisions is responsible for driving market demand in the hospital-associated labs segment.

The independent diagnostic laboratories segment is projected to be the fastest growing segment, owing to the increasing technological partnership and home sample collection services for improving accessibility and convenience.

Regional Segment Analysis of the Global Kidney Cancer Diagnostics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America Kidney Cancer Diagnostics Market Trends

North America is expected to hold the largest share of the global kidney cancer diagnostics market over the forecast period.

The North American region's supremacy includes the availability of well-established healthcare infrastructure and the adoption of diagnostic technologies. Furthermore, with an increasing awareness of kidney cancer and growing healthcare expenditure on diagnostic solutions, the kidney cancer diagnostics market is being driven.

U.S. Kidney Cancer Diagnostics Market Trends

The US has a significant presence of well-established healthcare infrastructure, with increased adoption of advanced diagnostic technologies. Government initiatives for spreading awareness about kidney cancer and increasing R&D activities contribute to propelling the kidney cancer diagnostics market.

Asia Pacific Kidney Cancer Diagnostics Market Trends

Asia Pacific is expected to grow at the fastest CAGR in the kidney cancer diagnostics market during the forecast period. This is attributed to the growing research in the field of kidney diagnosis, with manufacturers placing growing emphasis on R&D activities for launching novel series. This is further driven by the demand for cost-effective, portable, and non-invasive testing solutions. Additionally, the increasing cases of kidney cancer are anticipated to drive market demand.  

China Kidney Cancer Diagnostics Market Trends

Technological advancements in diagnostics are accelerating, along with an increasing government initiatives such as Healthy China 2020, which are supporting the kidney cancer diagnostics market. China is one of the major countries with the highest prevalence of kidney cancer, due to several lifestyle-related factors, which are responsible for driving market demand in the country.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global kidney cancer diagnostics market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Worldwide Top Key Players In The Kidney Cancer Diagnostics Market Include

• Myriad Genetics Inc.
• NeoGenomics Laboratories
• NanoString Technologies Inc.
• Sysmex Corporation
• Rosetta Genomics
• Illumina Inc.
• Glenmark
• Cobolong
• Quest Diagnostics Incorporated
• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent development

• In September 2025, according to a new study announced at the 39th annual International Bubble Conference, contrast-enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure.  
• In April 2025, an artificial intelligence (AI)-based model developed by UTSW researchers could help guide treatment decisions. Findings, published in Nature Communications, could lead to viable ways to use AI to guide treatment decisions for this and other types of cancer.

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the kidney cancer diagnostics market based on the following segments:

Global Kidney Cancer Diagnostics Market, By Test

• Immunohistochemistry
• Complete Blood Count
• Urine Test
• Blood Chemistry

Global Kidney Cancer Diagnostics Market, By Indication

• Renal Cell Carcinoma
• Transitional Cell Carcinoma
• Kidney Sarcoma
• Wilms Tumor
• Kidney Lymphoma

Global Kidney Cancer Diagnostics Market, By End-User

• Hospital-associated Labs
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Others

Global Kidney Cancer Diagnostics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa